

# Ascentage Pharma Group

## Patient-Centric Innovation

## Cutting-Edge Therapies

**Dr. Dajun Yang**

**January 11, 2023**

# Disclaimer

**DISCLAIMER FOR INVESTOR MATERIALS**

By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

The information in this presentation has been prepared by representatives of Ascentage Pharma Group International (the "**Company**", and together with its subsidiaries, the "**Group**") for use in presentations by the Group at investor meetings for information purposes. No part of this presentation should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of its directors, supervisors, officers, partners, employees, affiliates, agents, advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially.

This presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor any of its directors, supervisors, officers, partners, employees, affiliates, agents, advisors or representatives is under an obligation to update, revise or affirm.

The information communicated in this presentation contains certain statements that are or may be forward-looking. These statements typically contain words such as "will", "may", "expects", "forecasts", "plans" and "anticipates" and words of similar import. By their nature forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not rely on these forward-looking statements. The Company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company or any of its subsidiaries or affiliates in any jurisdiction. This presentation and the information contained herein is highly confidential and being furnished to you solely for your information and may not be reproduced or redistributed in any manner to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the United States, Canada, Australia, Japan, Hong Kong or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other national securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will be accepted.

By attending this presentation, you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Group and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Group. Any decision to purchase securities in the context of a proposed offering of securities, if any, should be made solely on the basis of information contained in an offering circular or prospectus prepared in relation to such offering.

By reviewing this presentation, you are deemed to have represented and agreed that you and any customers you represent are either (i) a "qualified institutional buyer" (within the meaning of Rule 144A under the United States Securities Act of 1933, as amended), or (ii) outside the United States. You are also deemed to have represented and agreed that you and any customers you represent are professional investors as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and any rules made thereunder.

# Year 2022：Accelerating Commercialization of Olverembatinib

**Revenue**

**RMB 95.76 million**

change as of same period last year

**636.9%**

**Cash Amount**

**RMB1.7 billion**

change as of same period last year

**Almost similar**




**2022 1H**

Commercial team of 100+ staff to cover 800+ hospitals, with Innovent

Covering >80% of the total CML market in China

- Included in 2022 edition of **CSCO** and **CACA** Guidelines for CML and Ph+ ALL
- Listed in 29 provinces and 230 cities **Huimin Medical Insurance**
- **NPP** (Named Patient Program) with Tanner Pharma, plans to cover over 130 countries and regions globally

# Global Commercialization Potential of Olverembatinib

## Market potential - Maximizing market value




For illustrative purposes of patient size

T315I mutation was the most frequent mutation detected in imatinib-, nilotinib-, and dasatinib resistant cases, accounting for 12.3%, 27.3%, and 34.1%[1]

### CML Full Approval NDA accepted by CDE

- Olverembatinib was granted **Priority Review Designation** and acceptance of **NDA for Full Approval**

### Global Commercialization

- Launched NPP with **Tanner Pharma**. Plans to cover **+130 countries and regions globally**
- Annual sales of Global CML Market is roughly **USD 6 bn**
- Annual sales of 2nd generation TKI (dasatinib, nilotinib) in 2020 and 2021 **> USD 4 bn**

| Drugs | Global Launch | WW sales (USD) | Indications |
|---|---|---|---|
| Ponatinib | 2013.01 | 469M (2021 whole year) | CML · ALL |
| Asciminib | 2021.10 | 56M (2022 first half-year) | CML |

Source:1. Chin J Hematol, 2020,41(06): 469-476

# Rapid Progress with Global Clinical Development Programs

| Compounds | Target | Indications | Preclinical | Ph-I | Ph-II | Registration Trial | NDA Approval | Trial Region | Rights Region |
|---|---|---|---|---|---|---|---|---|---|
| HQP1351 | BCR-ABL/KIT | Resistant CML | | | | | | | |
| | | Resistant CML，Ph+ ALL | | | | | 耐立克 奥雷巴替尼 olverembatinib | | |
| | | GIST | | | | | | | |
| | | Ph+ ALL | | | | | | | |
| APG-2575 | Bcl-2 Selective | r/r CLL/SLL (China) | | | | | | | |
| | | r/r CLL/SLL (Global) | | | | | | | |
| | | WM | | | | | | | |
| | | AML | | | | | | | |
| | | MDS | | | | | | | |
| | | MM | | | | | | | |
| | | T-PLL | | | | | | | |
| | | MCL | | | | | | | |
| | | ER+/HER2-BC and Solid Tumors | | | | | | | |
| APG-115 | MDM2-p53 | Melanoma and Solid Tumors(IO Combo) | | | | | | | |
| | | ACC | | | | | | | |
| | | AML,MDS | | | | | | | |
| APG-1387 | IAP/XIAP | Solid tumors(IO Combo) | | | | | | | |
| | | PDAC+ Chemo | | | | | | | |
| | | CHB | | | | | | | |
| APG-1252 | Bcl-2/Bcl-xL | NSCLC+ TKI | | | | | | | |
| | | SCLC+ Chemo | | | | | | | |
| | | NET | | | | | | | |
| | | NHL | | | | | | | |
| APG-2449 | FAK/ALK/ROS1 | NSCLC/ Solid tumors | | | | | | | |
| APG-5918 | EED Selective | Tumors/Hemoglobinopathy | | | | | | | |
| APG-265 | PROTACs MDM2 | Tumors | | | | | | | |
| UBX1967/1325 | Bcl Family | DME | | | | | | | |

● POC ● POC in progress

# Transition Towards a Fully-Integrated Global Biopharma Company

## Ascentage Pharma

## Global Headquarter/R&D Center and Manufacturing Facility in Suzhou, China

- GMP manufacturing equipment installation and qualification has been completed
- MAH type A certificate was issued in Nov 2022
- Capabilities for incubator and accelerator with angel innovation funding support

# Ascentage Pharma Hematology Portfolio




Lisaftoclax a Bcl-2 Selective Inhibitor




Olverembatinib Multi-Kinase BCR-ABL TKI




Alrizomadlin an MDM2-p53 inhibitor




APG-5918 a potent EED inhibitor

# Hematology Markets

Our Portfolio aligns with
Significant Growth Opportunities



# Recognitions by the Global Research Community

**ASCO 2022**

**7** **abstracts selected for presentations**

**Drug candidate： Olverembatinib ， Lisaftoclax ， Alrizomadlin ，APG-2449 ，APG-1252**


**AACR 2022**

**6** **abstracts selected for presentations**

**Drug candidate ： Lisaftoclax ，Alrizomadlin ，APG-2449 ，APG-5918 etc.**


**EHA 2022**

**1** **abstract selected for presentation**

**Drug candidate: Lisaftoclax**


**ASH 2022**

**4** **abstracts selected for oral presentation**

**Drug candidate: ： Olverembatinib, Lisaftoclax**

# HQP1351

## Olverembatinib

## Overview

The first and the only commercialized third generation BCR-ABL inhibitor in China

Targeting BCR-ABL mutants, including the T315I mutation

Best-in-class drug potential globally


olverembatinib





# 5 years roadmap: From IND to NDA Approval

- Clinical results of olverembatinib in CML were selected for oral presentation at ASH 2018-2022 and nominated as "**Best of ASH**" in 2019


2015

- 2015.04: submitted an IND TKI resistant CML in China

2016

- 2016.02: NMPA issued a "one-time umbrella approval" for r/r CML

2018

- 2018.07: held a pivotal Phase II clinical trial kick-off meeting with PI

2019

- 2021.03: received **Breakthrough Therapy Designation**
- 2021.11: received **NDA Approval**
- 2021.11: granted **Orphan Drug Designation (CML)** by European Commission
- 2021.12 granted **Orphan Drug Designation (AML)**

2020

2021

2022

- 2022.03: granted **Orphan Drug Designation (ALL)**
- 2022.04: Included in 2022 CSCO and CACA guidelines for CML and Ph+ ALL
- 2022.07: Received NDA acceptance for full approval and priority review by CDE
- 2022.07 : Gained Canada CTA clearance in Canada

# Ph I: Demonstrated Durable Efficacy and Differentiated Safety Profile

## Ph I: 5-year data for Olverembatinib

### Deep & Durable Duration of Response




### MMR Remission in T315i & Compound Mutations







**80% of patients remain on therapy for more than 5 years**




Jiang Q et al. ASH abstract #81, 2022

# Pivotal Trial: Deep & Durable Efficacy in T315i CML

## Cumulative Incidence of Responses, DOT, PFS & Response by Mutational Status

























T315I + additional mutations: F317L, M244V, E459K, F359V, Y253H, E255V, E450A, E459Q

Jiang Q et al. ASH abstract #81, 2022

# Pivotal Trial: Differentiated Safety Profile, enables long remissions

## A Proven Safety Profile in TKI resistant CML enables Long-term Remissions




Any grade arterial occlusive & venous thrombotic AEs occurred in 3.1% of patients, of which 1.6% were grade 3 or 4.

Jiang Q et al. ASH abstract #81, 2022

# US Ph Ib/II: Olverembatinib is Potentially Effective in Ponatinib Resistant CML

| Characteristic | CML-CP | Advanced Ph+ leukemia | Total |
|---|---|---|---|
| N | 38 | 13 | 51 |
| Line of therapy, n. (%) | | | |
| Primary refractory | 0 | 0 | 0 |
| Salvage 1 | 6 (15.8) | 1 (7.7) | 7 (13.7) |
| Salvage 2 | 11 (28.9) | 3 (23.1) | 14 (27.5) |
| Salvage 3+ | 18 (47.4) | 7 (53.8) | 25 (49.0) |
| Missing | 3 (7.9) | 2 (15.4) | 5 (9.8) |
| Prior ponatinib use, n (%) | 20 (52.6) | 8 (80.0) | 28 (54.9) |
| Resistant | 14 (70.0) | 7 (87.5) | 21 (75.0) |
| Intolerant | 6 (30.0) | 1 (12.5) | 7 (25.0) |
| *T315I* mutation | 14 (36.8) | 5 (38.5) | 19 (37.3) |

## Olverembatinib is Highly effective in Ponatinib Resistant CP-CML




## Durable Responses In Asciminib & Ponatinib Resistant CML Patients




Jabbour E et al. ASH abstract #82, 2022

# US Ph Ib/II: Safety & Activity in Ponatinib Resistant PH+ALL







| | 30 mg | 40 mg | 50 mg | Total |
|---|---|---|---|---|
| MCyR | 33.3 (1/3) | 100 (1/1) | 33.3 (1/3) | 42.9 (3/7) |
| CCyR | 33.3 (1/3) | - | 33.3 (1/3) | 28.6 (2/7) |
| MMR | 33.3 (1/3) | - | 33.3 (1/3) | 28.6 (2/7) |

Jabbour E et al. ASH abstract #82, 2022

# Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19

- Olverembatinib blocks the activity of several kinases essential for cytokine signalling, thereby dampening the Omicron-NTD-mediated cytokine release and reducing inflammations.
- Targeting multiple essential kinases that mediated cytokine release for SARS-CoV-2 and variants, may represent an attractive therapeutic option for treating moderate to severe COVID-19.







**Effect of Olverembatinib, Ponatinib, and Baricitinib on Omicron NTD-mediated cytokine release**




**Comparison of kinase inhibition profiles of Olverembatinib, Ponatinib, and Baricitinib**

Source: Gujral T et.al. EMBO Molecular Medicine, https://doi.org/10.1101/2022.02.07.479443

# APG-2575 Overview

Novel, orally administered Bcl-2 selective inhibitor, follow to Venclexta®

The second drug entered into pivotal phase II study globally

Best in class potential



# Lisaftoclax：Potential best-in class Bcl-2 inhibitor

1. More than 400 subjects enrolled into the APG-2575 studies, including r/r CLL, FL, MCL, MZL, DLBCL, WM, MM, AML, MDS and HCL patients

2. More than190 CLL patients have been treated with APG-2575 with POC achieved

   80% PR in Evaluable rrCLL/SLL Patients in US Phase I Study

   Demonstrated 67% ORR in Evaluable rrCLL/SLL Patients in doses ≥ 400 mg, China Phase I Study

3. Potential Best-in-Class with well tolerated safety profile, no DLT, no MTD reported

4. 5 Orphan Drug Designations (ODD): CLL, WM, MM, AML, FL

5. IND clearance for ER+ breast cancer and other solid tumors by FDA

6. Initiated registrational pivotal Phase II study for treatment of r/r CLL/SLL and the first patient has been dosed

# Global Phase II Study in the US: Safety+ Efficacy

## Daily Dose Ramp-up: More HCP & Patient Friendly & Eliminated TLS Risk

**Lisaftoclax + combination: lisaftoclax daily ramp-up, combination treatment starts < 2 weeks**




Source: Davids M et al. ASH abstract #964, 2022

# Global Phase II Study: Lisaftoclax shows Best-In-Class Safety Profile

## Lisaftoclax monotherapy

Reported Treatment Emergent AEs in ≥ 10% of pts (n = 46)




## Lisaftoclax + Rituximab

Reported Treatment Emergent AEs in ≥ 10% of pts (n = 39)




## Lisaftoclax + Acalabrutinib

Reported Treatment Emergent AEs in ≥ 10% of pts (n = 79)




**Lisaftoclax: differentiated safety as a single agent or in combination with rituximab or with acalabrutinib**

- No DLTs observed, the MTD has not been reached.
- TLS (n = 4; 2 clinical/2 laboratory), Dose reductions due neutropenia (n = 2, 1 in CD20)
- No treatment-related discontinuation or deaths

Source: Davids M et al. ASH abstract #964, 2022

# Global Phase II Study: Lisaftoclax Efficacy Summary

**In r/rCLL, with ORR of:**

- Monotherapy (n=43): **67.4%**
- Lisaftoclax + Rituximab (n=34): **79.4%**
- Lisaftoclax + Acalabrutinib: TN(n=16):**100%**
- Lisaftoclax + Acalabrutinib R/R (n=57): **98%**
  - Lisaftoclax + Acalabrutinib R/R **BTKi** naïve (n=46): **100%**
  - Lisaftoclax + Acalabrutinib R/R **BTKi** refractory (n=8): **87.5%**
  - Lisaftoclax + Acalabrutinib R/R **Venetoclax** refractory (n=4): **75%**




Source: Davids M et al. ASH abstract #964, 2022

# Strong Differentiation From Venetoclax

## APG-2575 Compared to Venetoclax

- Efficacious in BTK resistant WM PDX model in which Venetoclax shows no effect
- Daily ramp-up verse weekly ramp up
- Extremely low lab and clinical TLS
- Less neutropenia and thrombocytopenia
- Short T1/2 & exposure--potentially lower risk with better safety profile
- Second BCL-2 registration clinical trial globally
  First BCL-2 registration clinical trial for CLL in China

## Conclusion

### When Selectively Targeting BCL-2



# Lisaftoclax Potential

## Significant Opportunity for 2nd Gen, Better Safety Profile, More Patient & HCP Friendly BCL-2 Inhibitor

US CLL Patient Forecast




US AML Patient Forecast




*Significant Patient Growth in each Disease*










Source: Cerner Enviza CancerMPact 2022, Clarivate; Reported Sales and Consensus Forecasts



亞盛醫藥 Ascentage Pharma

# Alrizomadlin (APG-115)

MDM2-p53 Inhibitor

Activates p53 tumor suppression via MDM2-p53 PPI

Potential First-in-Class Drug



# Alrizomadlin : Mechanism

## APG-115 Delivers Anti-tumor Activity by Multiple MOAs

### Tumor Cells Apoptosis

Activates WT p53-dependent intrinsic apoptosis.

### T-Cell Mediated Anti-tumor Immunity

MDM2 protein expression is upregulated in T-cell and is essential in enhancing T-cell function via stabilization of STAT5 protein (Zhou et al. Nature 2021)



nature immunology ARTICLES

https://doi.org/10.1038/s41590-021-00888-3

Check for updates

The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity

Jiajia Zhou[1,2], Ilona Kryczek[1,2], Shasha Li[1,2], Xiong Li[1,2], Angelo Aguilar[3,4,5], Shuang Wei[1,2], Sara Grove[1,2], Linda Vatan[1,2], Jiali Yu[1,2], Yijian Yan[1,2], Peng Liao[1,2], Heng Lin[1,2], Jing Li[1,2], Gaopeng Li[1,2], Wan Du[1,2], Weichao Wang[1,2], Xueting Lang[1,2], Weimin Wang[1,2], Shaomeng Wang[3,4,5] and Weiping Zou[1,2,6,7,8,9]

Targeting the p53–MDM2 pathway to reactivate tumor p53 is a chemotherapeutic approach. However, the involvement of this pathway in CD8+ T cell-mediated antitumor immunity is unknown. Here, we report that mice with MDM2 deficiency in T cells exhibit accelerated tumor progression and a decrease in tumor-infiltrating CD8+ T cell survival and function. Mechanistically, MDM2 competes with c-Cbl for STAT5 binding, reduces c-Cbl-mediated STAT5 degradation and enhances STAT5 stability in tumor-infiltrating CD8+ T cells. Targeting the p53–MDM2 interaction with a pharmacological agent, APG-115, augmented MDM2 in T cells, thereby stabilizing STAT5, boosting T cell immunity and synergizing with cancer immunotherapy. Unexpectedly, these effects of APG-115 were dependent on p53 and MDM2 in T cells. Clinically, MDM2 abundance correlated with T cell function and interferon-γ signature in patients with cancer. Thus, the p53–MDM2 pathway controls T cell immunity, and targeting this pathway may treat patients with cancer regardless of tumor p53 status.

- APG-115 synergizes with IO and enhances T-cell mediated antitumor immunity



APG-115

Inhibition of MDM2-p53 interaction

## Host immunomodulator




Zhou J et al. Nat Immunol 2021;22:460-470.

STAT5, signal transducer and activator of transcription 5.

5. Tolcher AW et al. Molec Cancer Ther 2019;18:A086.

### Tumor microenvironment

Activates innate immunity by reprograming macrophages M2 to M1 to suppress tumorigenesis (Fang et al. 2019).

### Synthetic Lethality

Alrizomadlin in combination with Lisaftoclax overcomes Venetoclax resistance in AML (Zhai et al. Clinical Cancer Research 2023)



CLINICAL CANCER RESEARCH | TRANSLATIONAL CANCER MECHANISMS AND THERAPY

Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies

Yifan Zhai[1], Qiuqiong Tang[1], Douglas D. Fang[1], Jing Deng[1], Kaixiang Zhang[1], Qixin Wang[1], Yan Yin[1], Chengcheng Fu[2,3], Sheng-Li Xue[2,3], Na Li[1], Feng Zhou[1], and Dajun Yang[1,4]

Check for updates

ABSTRACT

**Purpose:** Despite approval of B-cell lymphoma (BCL)-2 inhibitor venetoclax for certain hematologic malignancies, its broader clinical benefit is curtailed by resistance. Our study aimed to determine if treatment with novel anticancer agents targeting BCL-2 and mouse double minute 2 (MDM2) could overcome venetoclax resistance in preclinical models.

**Experimental Design:** Venetoclax-sensitive and venetoclax-resistant acute myeloid leukemia (AML) and acute lymphoblastic leukemia cells and xenograft models were used to evaluate antitumor effects and underlying mechanisms associated with combined BCL-2 inhibitor lisaftoclax (APG-2575) and MDM2 inhibitor alrizomadlin (APG-115).

treatment resensitized (to apoptosis) venetoclax-resistant cellular and mouse models established via chronic drug exposure or genetically engineered with clinically relevant *BCL-2* gene mutations. Synergistic effects in reducing cellular viability and proliferation were also demonstrated in primary samples of patients with venetoclax-resistant AML treated with lisaftoclax and alrizomadlin *ex vivo*. Mechanistically, alrizomadlin likely primes cancer cells to BCL-2 inhibition-induced cellular apoptosis by downregulating expression of antiapoptotic proteins myeloid cell leukemia-1 and BCL–extra-large and upregulating pro-death BCL-2–associated X protein.

**Conclusions:** Lisaftoclax in combination with alrizomadlin over-

- APG-115 synergized with APG-2575 in inhibition of proliferation of the primary AML cells derived from venetoclax resistant patients *ex vivo*

# Alrizomadlin ：Clinical Development and Progress

**First-in-class potential**

- FDA has granted six ODDs to APG-115 for the treatment of soft tissue sarcoma, gastric cancer (GC),
- AML, Retinoblastoma, stage IIB-IV melanoma as well Neuroblastoma and 2 RPDs for neuroblastoma and Retinoblastoma

Granted a Fast Track Designation (FTD) by the FDA for the treatment of patients with unresectable or metastatic melanoma,

**Obtain clinical proof of concept**

## Clinical Development in the US

- Combination with KEYTRUDA® in collaboration with Merck US
- The results of a phase II clinical study of APG-115 in combination with pembrolizumab demonstrated promising antitumor activity and good tolerability, and specifically in the PD-1/PD-L1 inhibitor-resistant melanoma cohort reported 1 patient with CR, ORR of 24.1%, and DCR of 55.2%.
- A phase Ib/II study of APG-115 alone or in combination with azacytidine in AML/MDS/CMML (chronic myelomonocytic leukemia).
- An investigator-initiated monotherapy phase I/II study for treatment of salivary gland cancer.

## Clinical Development in China

- In May 2021, we initiated a trial of APG-115 in combination with PD-1 Inhibitor in patients with advanced liposarcoma or advanced solid tumors. First patient has been dosed for this trial.
- A phase Ib monotherapy study followed by a combination study with azacytidine or cytarabine in R/R MDS or AML.

# Alrizomadlin Plus Pembrolizumab: Efficacy

## Efficacy in all Cohorts

| Response | Melanoma (n = 32) | NSCLC (n = 19) | STK-11 (n = 5) | ATM (n = 11) | Liposarcoma (n = 17) | UC (n = 12) | MPNST (n = 6) |
|---|---|---|---|---|---|---|---|
| **ORR** (CR + PR) | 24.1% (7/29) | 6.7% (1/15) | 0 | 0 | 6.2% (1/16) | 12.5% (1/8) | 16.7% (1/6) |
| **DCR** (CR + PR + SD) | 55.2% (16/29) | 46.7% (7/15) | 25% (1/4) | 44.4% (4/9) | 81.2% (13/16) | 12.5% (1/8) | 66.7% (4/6) |
| **Best overall RECIST or iRECIST response** | | | | | | | |
| **CR** | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| **PR** | 6 (2 unconfirmed) | 1 | 0 | 0 | 1(unconfirmed) | 1 | 1(unconfirmed) |
| **SD** | 9 | 6 | 1 | 4 | 12 | 0 | 3 |

**ORR** and **DCR** are based on efficacy evaluable population; stable disease (**SD**) requires a minimum duration of 2 cycles. **CR**, complete response; **DCR** disease control rate; **PR**, partial response; **RECIST**, Response Evaluation Criteria in Solid Tumors; **UC**, urothelial carcinoma.

## Efficacy in Patients with IO Resistant Melanoma

| Response | Uveal (n = 8) | Mucosal (n = 5) | Cutaneous (n = 16) | Unknown primary (n = 3) | Total (N = 32) |
|---|---|---|---|---|---|
| **ORR** (CR + PR) | 14.3% (1/7) | 40% (2/5) | 26.7% (4/15) | 0 | **24.1%** (7/29*) |
| **DCR** (CR + PR + SD) | 71.4% (5/7) | 40% (2/5) | 46.7% (7/15) | 100% (2/2) | **55.2%** (16/29) |
| **Best overall RECIST or iRECIST response** | | | | | |
| **CR** | 0 | 0 | 1 | 0 | **1** |
| **PR** | 1 | 2 (1 unconfirmed) | 3 (1 unconfirmed) | 0 | **6** |
| **SD** | 4 | 0 | 3 | 2 | **9** |

Data cutoff: April 15, 2021.

* Total evaluable patient N: 29

## Efficacy in Patients with IO Resistant Cutaneous Melanoma Treated with APG-115 Plus Pembrolizumab




## Efficacy in Patients with IO Resistant Uveal Melanoma Treated with APG-115 Plus Pembrolizumab



# Alrizomadlin plus pembrolizumab: phase 2 study in adults and children with various solid tumors

## Safety

| | Any TEAE(s) | | |
|---|---|---|---|
| **Safety Population** | **Any Grade** | **Grade 3+** | **Serious** |
| **N (%)** | n (%) | n (%) | n (%) |
| **150 (100%)** | **145 (96.7)** | **86 (57.3)** | **52 (34.7)** |

| | Related TEAE(s) | | |
|---|---|---|---|
| **Safety Population** | **Any Grade** | **Grade 3+** | **Serious** |
| **N (%)** | n (%) | n (%) | n (%) |
| **150 (100%)** | **130 (86.7)** | **51 (34.0)** | **10 (6.7)** |

There have been no significant new safety alerts observed to date for this study that are either unanticipated and/or unmanageable.
*Corresponding events selected.
Data cutoff date: March 1, 2022.




- **This phase 2 study continues to demonstrate that alrizomadlin in combination with pembrolizumab is well tolerated in 150 subjects.**
- **These preliminary and interim results demonstrate clinical benefit of alrizomadlin combined with pembrolizumab in patients with melanoma with relapse/refractory disease, with a 55% and 73% DCR in cutaneous and uveal melanoma, respectively.**
- **Alrizomadlin combined with pembrolizumab demonstrates clinical benefit in patients with MPNST, with a 50% DCR, an orphan pediatric indication with no effective standard of care.**

# APG-1252

Bcl-2/Bcl-xL inhibitor

Combination use for the treatment of solid tumors and hematologic malignancies

Granted an ODD
for the treatment of SCLC

Potential Best-in-Class Drug



# APG-1252 plus Osimertinib：Efficacy

| Best response, n (%) | Dose determination 240mg (n=6) | Dose determination 160mg (n=5) | Expansion Arm-1 (n=20) | Expansion Arm-2 (n=22) |
|---|---|---|---|---|
| Partial response (unconfirmed) | 0 (0.0) | 1 (20.0) | 3 (15.0) | 13 (59.1) |
| Partial response (confirmed) | 0 (0.0) | 0 (0.0) | 1 (5.0) | 8 (36.4) |
| Stable disease | 5 (83.3) | 2 (40.0) | 13 (65.0) | 8 (36.4) |
| Progressive disease | 1 (16.7) | 2 (40.0) | 4 (20.0) | 1 (6.3) |
| DCR | 5 (83.3) | 3 (60.0) | 16 (80.0) | 21 (95.5) |

Dose determination and expansion Arm-1 N=31




Expansion Arm-2 N=22


- In dose-escalation: 1 PR in 11 evaluable TKI resistant patients
- In arm 1 of dose-expansion phase: 3 PRs and 13 SDs in 20 evaluable patients with ORR of 15% and DCR of 80%
- In arm 2 of dose-expansion phase, 13 PRs and 8 SDs in 22 evaluable patients, including 3 patients harboring EGFR Exon 20 insertion with ORR of 59.1% and DCR of 95.5%.

Combination treatment with APG-1252 and osimertinib at RP2D was safe and feasible.

Preliminary synergy and efficacy of both APG-1252 and osimertinib were also observed in some patients with EGFR TKI osimertinib-resistant and naïve NSCLC.

In treatment-naive and second-line patients with the EGFR T790M mutation or Exon 20 insertion, APG-1252 showed similar efficacy compared with navitoclax when combined with osimertinib

No significant difference in PK profiles of APG-1252 and osimertinib observed in combination treatment when compared to monotherapy.

IASLC 2021 World Conference on Lung Cancer
SEPTEMBER 8 - 14, 2021 I WORLDWIDE VIRTUAL EVENT

**Source: Li Zhang et al.(2021), Phase Ib Study of Pelcitoclax (APG-1252) in Combination With Osimertinib in Patients With EGFR TKI-Resistant NSCLC , 2021 World Conference on Lung Cancer (WCLC)**

# APG-1387

An Antagonist of
IAP/XIAP
(SMAC Mimetic) Dimmer




## Milestones & Clinical Developments

### CHB Development

- We have already completed a phase I study for the treatment of patients with CHB.
- The stage 1 safety evaluation of APG-1387 in combination with Entecavir (ETV) for a phase II study has completed. With well-tolerated safety data, the study moved forward to stage 2, efficacy evaluation of APG-1387 in combination with ETV compared to ETV monotherapy.

### Immuno-Oncology Development

- A phase I clinical trial in the United States, testing combination of APG-1387 with pembrolizumab, an anti-PD-1 mAb in solid tumors is ongoing.
- In China, a phase Ib/II clinical trial testing the combination of APG-1387 with toripalimab (拓益), another anti-PD-1 mAb, in solid tumors, is ongoing as well. The phase Ib patient enrollment has been completed and the trial has entered into phase II
- A phase I/II study that aims to investigate the combination of APG-1387 with chemotherapy, Nab-paclitaxel and Gemcitabine for treating advanced pancreatic cancer. First patient has been dosed in March 2021.

# APG-2449

ALK/FAK/ROS1




## Milestones & Clinical Developments

**APG-2449**

- APG-2449 is a novel, orally active, small molecule FAK/ALK/ROS1 triple ligase kinase inhibitor designed and developed by Ascentage. It is the first third-generation ALK inhibitor being developed in China.
- Pre-clinical data indicated that It is a very potential novel anticancer drug targeting FAK-expressing tumors and/or ALK/ROS1 fusion gene-positive non-small cell lung cancer.
- APG-2449 dose-dependently inhibited the expression of phosphorylated ALK protein (P-ALK) and its downstream proteins in Ba/F3 cells harboring ALK WT or EML4-ALK L1196M mutation.

**Clinical development of APG-2449**

- Dose Escalation study was completed for phase I study in which patients with ALK+ NSCLC or other solid tumors were enrolled. Enrollment is ongoing for Dose Expansion Cohorts for efficacy assessment in different patient population
- Based on the preliminary efficacy result of phase I study, the engagement with CDE for pivotal phase II registration study design is to be initiated.

# First-in-human phase 1 results of APG-2449 with second-generation TKI-resistant ALK/ROS1+ NSCLC or mesothelioma

## Efficacy Summaries for APG-2449 in Patient with ALK+NSCLC




Best tumor change (%) in pts with second-generation TKI resistant ALK+ NSCLC treated with RP2D of APG-2449




Best tumor change (%) in pts with TKI-naïve ALK/ROS1+ NSCLC treated with RP2D of APG-2449




Best tumor change (%) of brain metastases observed in pts with second-generation TKI resistant ALK+ NSCLC treated with APG-2449 at different assigned doses

- APG-2449 has demonstrated a favorable safety and PK profile and was well tolerated in 84 patients with NSCLC or mesothelioma.
- Preliminary efficacy was observed in patients who were resistant to second-generation TKIs, especially among those with brain metastases, and in TKI-naïve patients.
- Biomarker data suggests potential target engagement on FAK and immunomodulatory effects of APG-2449.
- RP2D was determined to be APG-2449 1,200 mg once daily.

# APG-5918

## EED inhibitor




## Target background and therapeutic rationale

**PRC2- an epigenetic regulator mainly consists of EZH1/2, EED, and SUZ12.**

**EZH2 and EED – catalytic subunit of PRC2, function as histone methyltransferase leading to gene silencing and dysregulation in many cancers. APG-5918 is efficacious on inhibition of H3K27me3**

**APG-5918 show similar activities to EZH2 inhibitors in vitro and in vivo.**

**EED inhibitors also effectively inhibit PRC2 containing a mutant EZH2 protein resistant to EZH2 inhibitors. EED inhibitor may inhibit the methyltransferase activities of both PRC2–EZH2 and PRC2–EZH1 and therefore may provide therapeutic(s) similar or complementary to the EZH2 inhibitors.**

**EZH2 inhibitor tazemetostat has shown promising efficacy and tolerable safety in epithelioid sarcoma (tazemetostat approved) and FL (tazemetostat approved)**

# Study Rationale – Advanced Solid tumor & NHL

## Mechanisms

- APG-5918 binds to the domain of EED that interacts with H3K27me3, which leads to a conformational change in the EED H3K27me3-binding pocket and prevents the interaction of EED with the histone EZH2, affecting the expression of its downstream target genes which play a role in carcinogenesis.

## Preclinical

- APG-5918 has shown potent in vitro and in vivo on-target pharmacological activity as a single agent or combine with other therapeutic agents in CDX and PDX models of NHL and solid tumors
- Preferentially, those with EZH mutations, BAP1 mutations, or are SMARCB1 deficiency

## IND clearance

- Gained IND approval for first-in-human study in patients with late-stage solid tumors or hematologic malignancies
- IND application to late-stage solid tumors or hematologic malignancies accepted by CDE
- Expect to file an IND to NMPA for the treatment of anemia diseases

# Pre-Clinical Assets

Focused on validated targets with clear biomarker, clinical indications and fast regulatory approval

High unmet medical needs




Transformative new technology

First-in-class or best-in-class potential

# IP Portfolio for Key Clinical Assets

| Key Clinical Assets | Estimated Patent Expired Year |
|---|---|
| HQP1351 | 2035-2041* |
| APG-2575 | 2037-2042* |
| APG-115 | 2035-2042* |
| APG-1387 | 2033-2042* |
| APG-1252 | 2034-2041* |
| APG-5918 | 2040-2042* |

*including composition, process, formulation, combination, use, new indication etc；(issued or pending)

Source: Company data Note: All data as of June 30, 2022

# Our Experienced Executives Team

**Dajun Yang, M.D., Ph.D.**
Co-Founder
Chairman & CEO

GEORGETOWN UNIVERSITY · ASCENTA THERAPEUTICS

**Shaomeng Wang Ph.D.**
Co-Founder
Chief Scientific Advisor

Professor at Michigan University. Prior Chief Editor of Journal of Medicinal Chemistry

Journal of Medicinal Chemistry

**Yifan Zhai, M.D., Ph.D.**
Chief Medical Officer

NATIONAL CANCER INSTITUTE · gsk · EXELIXIS · BAYER

**Gang Zhu.**
Chief Commercial Officer

Celgene · SANOFI · NOVARTIS

**Thomas Knapp**
SVP, General Counsel

BOEING · SUCAMPO · PAUL HASTINGS · ΣELLAS

**Jeff Kmetz**
Chief Business Officer

pharmacyclics · An AbbVie Company · Pulse Biosciences · ALEXION · BAYER

**Chongdong Fu, Ph.D.**
CMC head

復旦大學 FUDAN UNIVERSITY · 和黃医药 HUTCHMED

# Innovative and Proprietary Platform Delivering Potentially First and/or Best-in-Class Drugs

## Breakthrough Science

**205** issued patents

**600** pending applications

## Strong pipeline

**1** NDA Approval

**10+** indications

**12** novel compounds

**50+** clinical trials

**30+** INDs

## Dedicated team

**1** vision: building a global biopharmaceutical company

**20+** years commitment of executive team

**600+** employees

## Global development

**China, United States, Europe and Australia**

**Integrated global organization**

Source：Company database，as of June 30, 2022



# Ascentage Pharma Group

## Patient-Centric Innovation

## Cutting-Edge therapies

**Contact us:**

**ir@ascentage.com**

亞 盛 醫 藥

Ascentage Pharma

# Thank You

## CHINA

**Suzhou**

68 Xinqing Road , Suzhou Industrial Park,

Suzhou, Jiangsu, 215000

T : 86-512-85557777

**Taizhou**

QB3 Building, Medical City Avenue,

Taizhou, Jiangsu, 225300

T : 86-523-86201369

**Shanghai**

Suite 201, Building 5, 338 Jialilue Road,

Pudong, Shanghai, 201203

T : 86-21-61951088

**Guangzhou**

Room 2706, GIE Tower, 403 Huanshi Road East,

Yuexiu District, Guangzhou,

Guangdong, 510095

T : 86-20-28069260

**Beijing**

Suite 601, Zhengren Commercial Building,

9 Chongwenmenwai Street,

Dongcheng District, Beijing, 100062

T : 86-10-67082980

## UNITED STATES

**Rockville**

700 King Farm Blvd., Suite 510,

Rockville, MD 20850

T : +1 3012915658

## AUSTRALIA

**Sydney**

Level 26, 44 Market Street

Sydney, NSW, 2000

**Email: ir@ascentage.com**